{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:41:43Z","timestamp":1792449703734,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360805"],"award-info":[{"award-number":["82360805"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejmech.2024.116124","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T23:53:03Z","timestamp":1704325983000},"page":"116124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"special_numbering":"C","title":["Synthesis and clinical application of new drugs approved by FDA in 2023"],"prefix":"10.1016","volume":"265","author":[{"given":"Ya-Tao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Cheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Feng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2024.116124_bib1","article-title":"Vamorolone: first approval","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s40265-023-01874-9","article-title":"Omaveloxolone: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib3","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40265-023-01895-4","article-title":"Leniolisib: first approval","volume":"83","author":"Duggan","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib4","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s40265-023-01920-6","article-title":"Sulbactam\/Durlobactam: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib5","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1002\/phar.2802","article-title":"Sulbactam-durlobactam: a novel \u03b2-lactam-\u03b2-lactamase inhibitor combination targeting carbapenem-resistant Acinetobacter baumannii infections","volume":"43","author":"El-Ghali","year":"2023","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejmech.2024.116124_bib6","first-page":"180","article-title":"Improvement on the synthetic process of sulbactam","volume":"14","author":"Song","year":"2004","journal-title":"Chin. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib7","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","volume":"95","author":"Amani","year":"2023","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ejmech.2024.116124_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114367","article-title":"Paxlovid (Nirmatrelvir\/Ritonavir): a new approach to Covid-19 therapy?","volume":"162","author":"Hashemian","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116124_bib9","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116124_bib10","series-title":"Acid Addition Salt of 2-Isopropyl-4-(((n-Methyl)amino)methyl)thiazole and its Use in the Preparation of Ritonavir","author":"Bose","year":"2006"},{"key":"10.1016\/j.ejmech.2024.116124_bib11","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2215\/CJN.0000000000000278","article-title":"Taurolidine\/Heparin lock solution and catheter-related bloodstream infection in hemodialysis: a randomized, double-blind, active-control, phase 3 study","volume":"18","author":"Agarwal","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2024.116124_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jhin.2021.10.022","article-title":"The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis","volume":"123","author":"van den Bosch","year":"2022","journal-title":"J. Hosp. Infect."},{"key":"10.1016\/j.ejmech.2024.116124_bib13","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.21873\/invivo.12933","article-title":"The antiseptic and antineoplastic agent taurolidine modulates key leukocyte functions","volume":"36","author":"Wouters","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.ejmech.2024.116124_bib14","series-title":"Synthesis of Taurolidine, Purity Profiles and Polymorphs","author":"Berrios","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116124_bib15","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40265-023-01917-1","article-title":"Fezolinetant: first approval","volume":"83","author":"Lee","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib16","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1097\/GME.0000000000001621","article-title":"Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA)","volume":"27","author":"Santoro","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.ejmech.2024.116124_bib17","doi-asserted-by":"crossref","first-page":"5893","DOI":"10.1210\/jc.2019-00677","article-title":"Treatment of menopausal vasomotor symptoms with fezolinetant, a neurokinin 3 receptor antagonist: a phase 2a trial","volume":"104","author":"Depypere","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2024.116124_bib18","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1021\/acsmedchemlett.5b00117","article-title":"Optimization of novel antagonists to the neurokinin-3 receptor for the treatment of sex-hormone disorders (Part II)","volume":"6","author":"Hoveyda","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116124_bib19","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-019-0828-y","article-title":"Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives","volume":"18","author":"Cefalo","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.ejmech.2024.116124_bib20","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1124\/jpet.113.203364","article-title":"LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium\/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose","volume":"345","author":"Powell","year":"2013","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116124_bib21","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/clpt.2012.58","article-title":"LX4211, a dual SGLT1\/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial","volume":"92","author":"Zambrowicz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2024.116124_bib22","unstructured":"S.M.D. Paul, A. Perlberg, M.M. Zhao. Methods of Treating Diabetes. US 20130165395A1."},{"key":"10.1016\/j.ejmech.2024.116124_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122942","article-title":"RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity","volume":"10","author":"Probst","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2024.116124_bib24","series-title":"Pharmaceutical Use, and Characterization of Crystalline Forms of 2,2-difluoropropionamide Derivatives of Bardoxolone Methyl","author":"Anderson","year":"2013"},{"key":"10.1016\/j.ejmech.2024.116124_bib25","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-023-01885-6","article-title":"Zavegepant: first approval","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/WCO.0000000000000806","article-title":"Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment?","volume":"33","author":"Moreno-Ajona","year":"2020","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.ejmech.2024.116124_bib27","doi-asserted-by":"crossref","first-page":"6600","DOI":"10.1021\/acs.jmedchem.9b01810","article-title":"Blocking the CGRP pathway for acute and preventive treatment of migraine: the evolution of success","volume":"63","author":"Dubowchik","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib28","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3390\/brainsci12121612","article-title":"Gepants for acute and preventive migraine treatment: a narrative review","volume":"12","author":"Rissardo","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejmech.2024.116124_bib29","article-title":"A comprehensive review of zavegepant as abortive treatment for migraine","volume":"10","author":"Noor","year":"2022","journal-title":"Health Psychol. Res."},{"key":"10.1016\/j.ejmech.2024.116124_bib30","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1016\/j.bmcl.2013.04.012","volume":"23","author":"Chaturvedula","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116124_bib31","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s40265-023-01883-8","article-title":"Trofinetide: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2022.106704","article-title":"Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome","volume":"114","author":"Neul","year":"2022","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.ejmech.2024.116124_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jns.2008.12.003","article-title":"NNZ-2566: a Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke","volume":"278","author":"Bickerdike","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ejmech.2024.116124_bib34","series-title":"Effects of Glycyl-2 Methyl Prolyl Glutamate on Neurodegeneration","author":"Gluckman","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116124_bib35","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1021\/acs.jmedchem.7b00846","article-title":"Neuroactive steroids. 2. 3\u03b1-hydroxy-3\u03b2-methyl-21-(4-cyano-1H-pyrazol-1'-yl)-19-nor-5\u03b2-pregnan-20-one (SAGE-217): a clinical next generation neuroactive steroid positive allosteric modulator of the (\u03b3-aminobutyric acid)A receptor","volume":"60","author":"Martinez Botella","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib36","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1176\/appi.ajp.20220785","article-title":"Zuranolone for the treatment of postpartum depression","volume":"180","author":"Deligiannidis","year":"2023","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.ejmech.2024.116124_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-2999(86)90625-4","article-title":"Effects of 5-HT1A selective anxiolytics on lordosis behavior: interactions with progesterone","volume":"132","author":"Mendelson","year":"1986","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116124_bib38","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0149-2918(03)80159-5","article-title":"A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone","volume":"25","author":"Robinson","year":"2003","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.ejmech.2024.116124_bib39","doi-asserted-by":"crossref","first-page":"77s","DOI":"10.1097\/00004714-199006001-00014","article-title":"Gepirone in the treatment of major depression","volume":"10","author":"Jenkins","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116124_bib40","doi-asserted-by":"crossref","first-page":"6s","DOI":"10.1097\/00004714-199006001-00003","article-title":"Neurochemistry and neurophysiology of buspirone and gepirone: interactions at presynaptic and postsynaptic 5-HT1A receptors","volume":"10","author":"Yocca","year":"1990","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejmech.2024.116124_bib41","series-title":"Process for the Synthesis of Gepirone","author":"Colombano","year":"2020"},{"key":"10.1016\/j.ejmech.2024.116124_bib42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metabol. Pharmacokinet."},{"key":"10.1016\/j.ejmech.2024.116124_bib43","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for Anemia in CKD: a 28-day, phase 2a randomized Trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejmech.2024.116124_bib44","series-title":"Preparation of N-Substituted Pyrimidine-Trione Amino Acid Derivatives as Prolyl Hydroxylase Inhibitors","author":"Duffy","year":"2007"},{"key":"10.1016\/j.ejmech.2024.116124_bib45","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s40265-023-01964-8","article-title":"Momelotinib: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib46","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/leu.2009.50","article-title":"CYT387, a selective JAK1\/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients","volume":"23","author":"Pardanani","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2024.116124_bib47","first-page":"195","article-title":"Momelotinib, the next JAK2 inhibitor?","volume":"21","author":"Masarova","year":"2023","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2024.116124_bib48","series-title":"N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide [CYT387] or a Related Compound","author":"Smith","year":"2012"},{"key":"10.1016\/j.ejmech.2024.116124_bib49","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejmech.2024.116124_bib50","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1124\/dmd.123.001290","article-title":"Absorption, distribution, metabolism, and excretion of [(14)C]iptacopan in healthy male volunteers and in in vivo and in vitro studies","volume":"51","author":"James","year":"2023","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2024.116124_bib51","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ekir.2023.01.041","article-title":"Targeting the alternative complement pathway with iptacopan to treat IgA nephropathy: design and rationale of the APPLAUSE-IgAN study","volume":"8","author":"Rizk","year":"2023","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ejmech.2024.116124_bib52","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1182\/blood-2009-09-244285","article-title":"A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement","volume":"115","author":"Lindorfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116124_bib53","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1021\/acs.jmedchem.9b01870","article-title":"Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic acid (LNP023), a factor B inhibitor specifically designed to be applicable to treating a diverse array of complement mediated diseases","volume":"63","author":"Mainolfi","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib54","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-08-801191","article-title":"Effective \"activated PI3K\u03b4 syndrome\"-targeted therapy with the PI3K\u03b4 inhibitor leniolisib","volume":"130","author":"Rao","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116124_bib55","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (Leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116124_bib56","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1007\/s40265-023-01928-y","article-title":"Ritlecitinib: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib57","doi-asserted-by":"crossref","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","article-title":"Discovery of a JAK3-selective inhibitor: functional differentiation of JAK3-selective inhibition over pan-JAK or JAK1-selective inhibition","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2024.116124_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.950450","article-title":"The efficacy and safety of JAK inhibitors for alopecia areata: a systematic review and meta-analysis of prospective studies","volume":"13","author":"Yan","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2024.116124_bib59","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.2147\/DDDT.S172638","article-title":"Role of janus kinase inhibitors in the treatment of alopecia areata","volume":"12","author":"Triyangkulsri","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2024.116124_bib60","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1021\/acs.jmedchem.6b01694","article-title":"Design of a janus kinase 3 (JAK3) specific inhibitor 1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) allowing for the interrogation of JAK3 signaling in humans","volume":"60","author":"Thorarensen","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib61","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1021\/ml500389m","article-title":"Discovery of APD334: design of a clinical stage functional antagonist of the sphingosine-1-phosphate-1 receptor","volume":"5","author":"Buzard","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116124_bib62","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(12)60150-0","article-title":"Ulcerative colitis","volume":"380","author":"Ord\u00e1s","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2024.116124_bib63","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2217\/imt-2022-0255","article-title":"Etrasimod for the treatment of ulcerative colitis","volume":"15","author":"Wils","year":"2023","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejmech.2024.116124_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s40265-022-01709-z","article-title":"Palovarotene: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib65","first-page":"437","article-title":"Fibrodysplasia ossificans progressiva: diagnosis, management, and therapeutic horizons","volume":"2","author":"Pignolo","year":"2013","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"10.1016\/j.ejmech.2024.116124_bib66","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bone.2016.06.014","article-title":"Targeted stimulation of retinoic acid receptor-\u03b3 mitigates the formation of heterotopic ossification in an established blast-related traumatic injury model","volume":"90","author":"Pavey","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.ejmech.2024.116124_bib67","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3390\/biomedicines8090325","article-title":"Clinical aspects and current therapeutic approaches for FOP","volume":"8","author":"Kitoh","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2024.116124_bib68","series-title":"Preparation of New Retinoids for the Treatment of Emphysema, Cancer and Dermatological Disorders","author":"Lapierre","year":"2002"},{"key":"10.1016\/j.ejmech.2024.116124_bib69","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejmech.2024.116124_bib70","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1001\/jamaneurol.2022.2480","article-title":"Efficacy and safety of vamorolone vs placebo and prednisone among boys with duchenne muscular dystrophy: a randomized clinical trial","volume":"79","author":"Guglieri","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.ejmech.2024.116124_bib71","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.bmc.2013.02.009","article-title":"VBP15: preclinical characterization of a novel anti-inflammatory delta 9,11 steroid","volume":"21","author":"Reeves","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib72","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1182\/blood-2019-126114","article-title":"Loxo-305, a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations","volume":"134","author":"Gomez","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116124_bib73","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221101697","article-title":"The potential of pirtobrutinib in multiple B-cell malignancies","volume":"13","author":"Jensen","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.ejmech.2024.116124_bib74","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJMoa2114110","article-title":"Mechanisms of resistance to noncovalent Bruton's tyrosine kinase inhibitors","volume":"386","author":"Wang","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2024.116124_bib75","series-title":"Processes and Intermediates for the Preparation of (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide","author":"Jose","year":"2022"},{"key":"10.1016\/j.ejmech.2024.116124_bib76","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-023-01861-0","article-title":"Elacestrant: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib77","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221113694","article-title":"Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role","volume":"14","author":"Lloyd","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejmech.2024.116124_bib78","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13058-019-1230-0","article-title":"Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4\/6 inhibitors","volume":"21","author":"Patel","year":"2019","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116124_bib79","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116124_bib80","series-title":"Selective Estrogen Receptor Modulator","author":"Hamaoka","year":"2012"},{"key":"10.1016\/j.ejmech.2024.116124_bib81","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11912-023-01389-2","article-title":"An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape","volume":"25","author":"Bystrom","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.ejmech.2024.116124_bib82","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1182\/blood-2009-05-222034","article-title":"AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)","volume":"114","author":"Zarrinkar","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2024.116124_bib83","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib84","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.4161\/15384047.2014.964087","article-title":"Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy","volume":"15","author":"Sun","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2024.116124_bib85","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2024.116124_bib86","series-title":"Quinazoline Derivatives","author":"Su","year":"2009"},{"key":"10.1016\/j.ejmech.2024.116124_bib87","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1538-7445.AM2016-2132","article-title":"The novel, rationally-designed, ALK\/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors","volume":"76","author":"Zhai","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2024.116124_bib88","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1535-7163.MCT-21-0395","article-title":"Resistance profile and structural modeling of next-generation ROS1 tyrosine kinase inhibitors","volume":"21","author":"Keddy","year":"2022","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116124_bib89","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2024.116124_bib90","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1158\/2159-8290.CD-18-0484","article-title":"Repotrectinib (TPX-0005) is a next-generation ROS1\/TRK\/ALK inhibitor that potently inhibits ROS1\/TRK\/ALK solvent-front mutations","volume":"8","author":"Drilon","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2024.116124_bib91","series-title":"Gialir Macrocyclic Polymorph","author":"Cui","year":"2018"},{"key":"10.1016\/j.ejmech.2024.116124_bib92","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1158\/1535-7163.MCT-11-0824-T","article-title":"Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background","volume":"11","author":"Davies","year":"2012","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116124_bib93","series-title":"Substituted Piperidines Having Protein Kinase Inhibiting Activity","author":"Woodhead","year":"2010"},{"key":"10.1016\/j.ejmech.2024.116124_bib94","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1158\/1535-7163.MCT-10-0034","article-title":"Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design","volume":"9","author":"Wei","year":"2010","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2024.116124_bib95","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41698-022-00308-1","article-title":"Molecular pathogenesis of desmoid tumor and the role of \u03b3-secretase inhibition","volume":"6","author":"Federman","year":"2022","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.ejmech.2024.116124_bib96","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1016\/j.bmcl.2010.12.118","article-title":"Design, synthesis, and in vivo characterization of a novel series of tetralin amino imidazoles as \u03b3-secretase inhibitors: discovery of PF-3084014, Bioorg","volume":"21","author":"Brodney","year":"2011","journal-title":"Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2024.116124_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.709712","article-title":"Deciphering the action of perfluorohexyloctane eye drops to reduce ocular discomfort and pain","volume":"8","author":"Delicado-Miralles","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2024.116124_bib98","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1097\/ICO.0000000000002622","article-title":"A randomized clinical study (SEECASE) to assess efficacy, safety, and tolerability of NOV03 for treatment of dry eye disease","volume":"40","author":"Tauber","year":"2021","journal-title":"Cornea"},{"key":"10.1016\/j.ejmech.2024.116124_bib99","series-title":"Preparation of 1,1,1,2,2,3,3,4,4,5,5,6,6-tridecafluorotetradecane","author":"Zhou","year":"2023"},{"key":"10.1016\/j.ejmech.2024.116124_bib100","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s40265-023-01947-9","article-title":"Lotilaner ophthalmic solution 0.25%: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib101","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s13071-017-2470-4","article-title":"The novel isoxazoline ectoparasiticide lotilaner (Credelio\u2122): a non-competitive antagonist specific to invertebrates \u03b3-aminobutyric acid-gated chloride channels (GABACls)","volume":"10","author":"Rufener","year":"2017","journal-title":"Parasites Vectors"},{"key":"10.1016\/j.ejmech.2024.116124_bib102","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1126\/science.8380942","article-title":"GABA-activated chloride channels in secretory nerve endings","volume":"259","author":"Zhang","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2024.116124_bib103","series-title":"Preparation Method of Isoxazoline Insecticide","author":"Jiang","year":"2021"},{"key":"10.1016\/j.ejmech.2024.116124_bib104","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40265-023-01848-x","article-title":"Bexagliflozin: first approval","volume":"83","author":"Hoy","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib105","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.phrs.2011.01.001","article-title":"EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db\/db mice and prolongs the survival of stroke-prone rats","volume":"63","author":"Zhang","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2024.116124_bib106","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1080\/14656566.2021.1959915","article-title":"Bexagliflozin for type 2 diabetes: an overview of the data","volume":"22","author":"Azzam","year":"2021","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.ejmech.2024.116124_bib107","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2215\/CJN.09380822","article-title":"Kidney-protective effects of SGLT2 inhibitors","volume":"18","author":"Palmer","year":"2023","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ejmech.2024.116124_bib108","doi-asserted-by":"crossref","first-page":"84","DOI":"10.2174\/1574886313666180226103408","article-title":"Risks associated with SGLT2 inhibitors: an overview","volume":"13","author":"Singh","year":"2018","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.ejmech.2024.116124_bib109","series-title":"Preparation of Benzylbenzene Glycoside Derivatives as Antidiabetic Agents","author":"Song","year":"2009"},{"key":"10.1016\/j.ejmech.2024.116124_bib110","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-023-01864-x","article-title":"Sparsentan: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2024.116124_bib111","doi-asserted-by":"crossref","first-page":"17117","DOI":"10.1021\/jm049548x","article-title":"Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2'-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics","volume":"48","author":"Murugesan","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2024.116124_bib112","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrneph.2012.58","article-title":"Pathogenesis of IgA nephropathy","volume":"8","author":"Lai","year":"2012","journal-title":"Nat. Rev. Nephrol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523424000047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T14:55:41Z","timestamp":1736866541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523424000047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":112,"alternative-id":["S0223523424000047"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116124","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and clinical application of new drugs approved by FDA in 2023","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2024.116124","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"116124"}}